Genentech Medical’s Post

Dear Colleagues,   It is with great pleasure that we extend to you an invitation to partake in the 1st Extracellular Vesicles Conference 2024 (TURSEV-24) at Middle East Technical University (METU) in Ankara, Türkiye on September 20-21, 2024.   TURSEV-24 serves as an eminent platform, uniting leading researchers, scholars, industry experts, and students in a collective endeavor to delve into challenges and opportunities in extracellular vesicle research. With a rapidly advancing landscape, collaborative endeavors assume paramount significance in bridging gaps between basic science and clinical applications.   Our inspiring program features keynote speeches, panels, and workshops spotlighting cutting-edge discoveries and methodologies. Together, we shall chart the trajectory of extracellular vesicle research, envisaging its transformative potential in revolutionizing human health.   We cordially invite you to contribute to the discourse by submitting abstracts for presentations and sharing your expertise. Your insights and contributions are indispensable in propelling this dynamic and vibrant field forward.   Embark with us on an odyssey to unravel the enigmas surrounding extracellular vesicles!   Visit our website for more details and registration. www.tursev.org     With kindest regards,   On behalf of the Organizing Committee   Dr. Burak Derkuş, Ankara University Dr. Fatih İnci, Bilkent University UNAM Dr. Ahmet Acar, METU Fatih Inci Burak Derkuş Ahmet Acar #ExtracellularVesicles #Exosomes #Oncosomes #Apoptosomes #MicrobialVesicles #Characterization #Diagnosis #Pathology #RegenerativeMedicine #Drug #Vaccines #VeterinaryClinics #Medical #Cosmetics #IndustrialExosomes

Check out the Pharmacy Times Continuing Education™ CE activity titled: Foundations in the Management of Eosinophilic Esophagitis: Pathophysiology, Clinical, Economic, and Quality of Life Burden. The online activity is now posted and available at this link: https://lnkd.in/eyvRQqtH Part one of a three part series!

Innovating Kidney Research: NIPOKA GmbH Leading the Way in Greifswald's Thriving Health Tech Scene Our Managing Director Thomas Einsfelder and consultant Laura Maslo had the pleasure of meeting with Prof. Dr. Nicole Endlich and Tim Endlich, the Managing Directors of NIPOKA GmbH, at the Institute of Anatomy and Cell Biology (UMG) in Greifswald. This visit offered inspiring insights into the innovative work being carried out by NIPOKA and highlighted exciting opportunities for collaboration in Mecklenburg-Vorpommern's thriving health technology sector. NIPOKA is at the forefront of medical innovation, specializing in groundbreaking methods for the quantitative analysis of podocyte morphology—specialized kidney cells—using advanced 3D-structured illumination microscopy. Their flagship product, PEMP (Podocyte Exact Morphology Measurement Procedure), enables precise analysis of kidney tissue samples for research purposes and holds potential for future clinical applications. Why It Matters NIPOKA's cutting-edge research underscores the importance of fostering regional collaboration to strengthen value chains and drive innovation. By engaging directly with the leadership team, the discussion focused on how the local ecosystem can better support companies like NIPOKA in scaling their impact and addressing emerging needs. During the visit, plans for the upcoming European Renal Cell Study Group (ERCSG) Meeting were shared. Organized by Prof. Dr. Nicole Endlich and her team, this prestigious event will take place from April 3–6, 2025, at the Schloss Hotel Fleesensee. The meeting promises to be a global platform for advancing kidney cell research, featuring inspiring lectures, dynamic discussions, and opportunities to connect with leading international experts in nephrology. A heartfelt thank you to the team at NIPOKA for the warm welcome and engaging exchange! The visit highlighted not only the innovative work being conducted but also the shared commitment to advancing medical technology and healthcare solutions. Do you have questions about our visit? Write us in the comments! #InvestinMV #TeamMV #Nipoka #Greifswald

Banks, of course, should have a lot of cash and diversified investment portfolios to leverage economic strength. In medical research, there’s a different kind of bank called a #biobank, and it thrives by receiving DNA specimens from patients who volunteer to participate by providing a vial of blood. The more samples that are received, the better the opportunity for researchers to discover advanced, personalized treatment options. The Colorado Center for Personalized Medicine, a partnership between UCHealth and University of Colorado Anschutz Medical Campus, has now invited patients from UCHealth Parkview to take part in the program. To learn more: https://lnkd.in/dA3AEts8 #Biobanking #Biorepository #Cryopreservation #PersonalizedMedicine #Genomics #PrecisionMedicine #UCHealth #HealthTech #Biotechnology #ClinicalResearch #HealthData #Pueblo

🧬 DID YOU KNOW 🧬 Xytex maintains selective and recommended genetic screening aligning with the American College of Obstetricians and Gynecologists (ACOG) and ACMG - American College of Medical Genetics and Genomics. With expanded carrier testing, Xytex donors joining the program after February 2023 include screening for 524 inherited conditions including American College organization recommendations. 🌟 The American College of Obstetricians and Gynecologists produce practice guidelines for health care professionals and educational materials for patients, facilitate programs and initiatives to improve women’s health, and advocate for members and patients. 🌟 The American College of Medical Genetics and Genomics improve patient care, establish standards of care and laboratory policy, and educate members on important advances. Learn more about the donor screening process at https://lnkd.in/ghGNSaW8 #Xytex #DidYouKnow

Prof. Itziar de Lecuona, PhD from Universitat de Barcelona 🇪🇸 teaches the consortium about important #ethical and crucial #legal aspects of using #AI-assisted tools in #science: 👉 We need to take full responsibility over the content and perform solid #training of young researchers prior to using AI-assisted tools. ⚠️ Whoever uses them, must be aware of the #risks. Great #Masterclass 🎓, rounding off the 6th #GeneralAssembly of #MicrobPredict in #Ljubljana, Slovenia 🇸🇮 European Commission European Liver Patients' Association - ELPA European Foundation for the Study of Chronic Liver Failure (EF CLIF) EASL | The Home of Hepatology

We’re thrilled to announce our newest paper in #FrontlineGastroenterology is now published online. "From O’Shaughnessy to Opportunity: Innovating #HepatologyTrials in the UK" The review explores the challenges and opportunities in conducting clinical trials for #liverdisease, particularly decompensated #cirrhosis, within the UK. Working in collaboration with Oliver Tavabie, Gautam Mehta, Daniel Green and other experts, we reflect on historical achievements, current obstacles, and future directions to enhance hepatology clinical trial performance, emphasising the necessity of innovative approaches post-COVID-19 pandemic. The review draws on insights from the #OShaughnessy report and the UK-Chronic Liver Failure network (UK-CLIF), highlighting key areas for improvement and collaboration. Highlights from the report: ➡ Recommendations from the O’Shaughnessy Report ➡ Addressing Representation and Diversity ➡ Connecting Stakeholders and Standardising Care ➡ Innovating Trial Design and Delivery ➡ Enhancing Clinical Trial Career Pathways ➡ Developing the Commercial Hepatology Trials Sector To read the full review head to the PHARMExcel website 👉 https://lnkd.in/dkg42TwU #Heptology #ClinicalTrials #Gastroenterology #LiverDisease #FrontlineGastroenterology

𝑾𝒂𝒗𝒆 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆𝒔 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝑷𝒓𝒐𝒎𝒊𝒔𝒊𝒏𝒈 𝑷𝒉𝒂𝒔𝒆 𝑰𝒃/𝑰𝑰𝒂 𝑹𝒆𝒔𝒖𝒍𝒕𝒔 𝒇𝒐𝒓 𝑾𝑽𝑬-003 𝒊𝒏 𝑯𝒖𝒏𝒕𝒊𝒏𝒈𝒕𝒐𝒏’𝒔 𝑫𝒊𝒔𝒆𝒂𝒔𝒆 𝑻𝒓𝒊𝒂𝒍 Wave Life Sciences has announced promising results for its investigational antisense oligonucleotide WVE-003 in a Phase Ib/IIa trial for Huntington’s disease! 🧬💊 At 24 weeks, WVE-003 led to a 46% reduction in mutant huntingtin (HTT) levels in cerebrospinal fluid compared to placebo, with the effect persisting until 28 weeks at a 44% reduction. 📉✨ Importantly, WVE-003 preserved wildtype HTT levels throughout the assessment period, confirming its allele-selective action. The trial also showed significant increases in wildtype HTT levels versus placebo. 🔬👏 Wave Life Sciences is hiring for a Manager/Sr. Manager, Medical Communications (Lexington, MA) https://lnkd.in/eGVsNEsm #Biotech #HuntingtonsDisease #Research #Healthcare

Honored to present at the excellent annual #IEPS meeting yesterday. Reflecting on 199 years since the first documented description of human "Foie Gras" in a French anatomy book (1825) - interestingly, associated with tuberculosis - the pandemic du jour of early 19th century - to today's #MASLD, and what a remarkable year it's been in this field. Even when limiting our scope to hormone-receptor based interventions, we face fascinating questions: the overwhelming metabolic impact of gut peptides, intrahepatic pathways despite absent parenchymal receptors, the degree of synergism in multiple receptor coagonists, and whether remarkable weight effects translate to tangible liver health endpoints. It's truly an exciting time as we approach meaningful clinical impact. And yes - couldn't resist using my final slide to share that we're recruiting! My lab is seeking a researcher and technician for innovative projects in mouse-derived liver organoids. #LiverResearch #MASLD #Organoids

🎉 Proud to Announce Our Latest Publication in Cureus Journal of Medical Science! 🎉 I am thrilled to share our newest article: "A1 Phenotype: A Shadow Behind Pulmonary Embolism", recently published in Cureus. This work marks a significant milestone in our research on venous thromboembolic disease in the Colombian Caribbean. We have identified the A1 phenotype as a key risk factor for the development of pulmonary embolism (PE), along with elevated levels of coagulation factor VIII. 🔬 What makes this study unique? For the first time, the relationship between the A1 phenotype and PE risk is explored in a Colombian population. Our findings suggest the need for more detailed and personalized evaluations in patients at risk for PE. This study could pave the way for new strategies in the prevention and treatment of this serious condition. I deeply appreciate the dedication and hard work of my co-authors and collaborators who made this project possible. 📖 I invite you to read the full article here: https://lnkd.in/g8SYegXW This is just the beginning of future research that we hope will continue to contribute to the understanding and management of pulmonary embolism. #Research #PublicHealth #Medicine #Hematology #Thromboembolism #A1Phenotype #ScientificPublication